Treatment of keloid disorder is an area of unmet medical need. Current treatments for keloid
partially address small and localized keloids, yet there are no wholly satisfactory or
effective treatments for patients with extensive keloids. Such patients may benefit from
effective systemic treatments.
Sorafenib has the potential to regulate the three known dysregulated biological pathways in
keloid tissue.